Last Updated : July 24, 2024
Details
Generic Name:
vorinostat
Project Status:
Not filed
Therapeutic Area:
Cutaneous T-cell lymphoma
Manufacturer:
Merck Canada Inc.
Brand Name:
Zolinza
Project Line:
Reimbursement Review
Project Number:
NS0015-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
For the treatment of cutaneous manifestations in patients with advanced cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease subsequent to prior systemic therapies.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024